Jeffrey H Ruth
Overview
Explore the profile of Jeffrey H Ruth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1056
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muraoka S, Brodie W, Mattichak M, Gurrea-Rubio M, Ikari Y, Foster C, et al.
Arthritis Rheumatol
. 2024 Aug;
77(1):80-91.
PMID: 39175116
Objective: Systemic sclerosis (SSc) is an autoimmune multisystem disease with poorly understood pathogenesis and ineffective treatment options. Soluble CD13 (sCD13), generated by the cleavage of cell surface CD13 via matrix...
2.
Gurrea-Rubio M, Wu Q, Amin M, Tsou P, Campbell P, Amarista C, et al.
Cancer Immunol Immunother
. 2024 Jan;
73(2):34.
PMID: 38280067
Immune checkpoint inhibitors (ICIs) have demonstrated efficacy and improved survival in a growing number of cancers. Despite their success, ICIs are associated with immune-related adverse events that can interfere with...
3.
Gurrea-Rubio M, Wu Q, Amin M, Tsou P, Campbell P, Amarista C, et al.
Res Sq
. 2023 Oct;
PMID: 37886483
Immune checkpoint inhibitors (ICIs) have demonstrated efficacy and improved survival in a growing number of cancers. Despite their success, ICIs are associated with immune-related adverse events that can interfere with...
4.
Mammalian Glycosylation Patterns Protect Citrullinated Chemokine MCP-1/CCL2 from Partial Degradation
Korchynskyi O, Yoshida K, Korchynska N, Czarnik-Kwasniak J, Tak P, Pruijn G, et al.
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36768186
Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a potent chemotactic agent for monocytes, primarily produced by macrophages and endothelial cells. Significantly elevated levels of MCP-1/CCL2 were found in synovial fluids of patients...
5.
Umar S, Singh A, Chourasia M, Rasmussen S, Ruth J, Ahmed S
Front Immunol
. 2022 Aug;
13:928436.
PMID: 36032089
O-GlcNAcylation is a reversible post-translational modification that regulates numerous cellular processes, including embryonic development as well as immune responses. However, its role in inflammation remains ambiguous. This study was designed...
6.
Tsou P, Lu C, Gurrea-Rubio M, Muraoka S, Campbell P, Wu Q, et al.
J Clin Invest
. 2022 Apr;
132(11).
PMID: 35439173
CD13, an ectoenzyme on myeloid and stromal cells, also circulates as a shed, soluble protein (sCD13) with powerful chemoattractant, angiogenic, and arthritogenic properties, which require engagement of a G protein-coupled...
7.
Vichaikul S, Gurrea-Rubio M, Amin M, Campbell P, Wu Q, Mattichak M, et al.
JCI Insight
. 2022 Mar;
7(9).
PMID: 35349485
Binding of the bromodomain and extraterminal domain proteins (BETs) to acetylated histone residues is critical for gene transcription. We sought to determine the antifibrotic efficacy and potential mechanisms of BET...
8.
Ruth J, Gurrea-Rubio M, Athukorala K, Rasmussen S, Weber D, Randon P, et al.
JCI Insight
. 2021 Jan;
6(5).
PMID: 33497367
Limitations of checkpoint inhibitor cancer immunotherapy include induction of autoimmune syndromes and resistance of many cancers. Since CD318, a novel CD6 ligand, is associated with the aggressiveness and metastatic potential...
9.
Lanigan T, Rasmussen S, Weber D, Athukorala K, Campbell P, Fox D, et al.
J Biol Methods
. 2020 Jun;
7(2):e133.
PMID: 32577423
Cancer immunotherapy is a rapidly advancing and viable approach to treating cancer along with more traditional forms of therapy. Real-time cell analysis technologies that examine the dynamic interactions between cancer...
10.
Li Y, Ruth J, Rasmussen S, Athukorala K, Weber D, Amin M, et al.
Arthritis Rheumatol
. 2020 Apr;
72(9):1505-1513.
PMID: 32307907
Objective: CD6 is an important regulator of T cell function that interacts with the ligands CD166 and CD318. To further clarify the significance of CD6 in rheumatoid arthritis (RA), we...